| Cubicin (daptomycin) / Merck (MSD) |
NCT00651131: Cubicin(R) for Complicated Post-surgical Wound Infections |
|
|
| Terminated | 4 | 69 | NA | daptomycin, Cubicin, daptomycin for injection, Cubicin (daptomycin for injection) | Cubist Pharmaceuticals LLC | Wound Infections | 03/05 | 03/05 | | |
NCT00295178: Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas |
|
|
| Completed | 4 | 80 | US | Daptomycin, Vancomycin | Cubist Pharmaceuticals LLC | Cellulitis | 08/06 | 08/06 | | |
NCT00102947: Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections |
|
|
| Terminated | 4 | 72 | US | daptomycin (up to 14 days) | Cubist Pharmaceuticals LLC | Soft Tissue Infections | 11/06 | 11/06 | | |
| Terminated | 4 | 52 | Europe | Daptomycin | Novartis | Staphylococcal Skin Infections | 11/07 | | | |
NCT00572260: A Pilot Study of Daptomycin for Antimicrobial Prophylaxis |
|
|
| Terminated | 4 | 11 | US | daptomycin 6 mg/kg IV | Duke University, Cubist Pharmaceuticals LLC | Antimicrobial Prophylaxis | 09/08 | 09/08 | | |
NCT00401960: Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis. |
|
|
| Terminated | 4 | 6 | US | Daptomycin, Cubicin | Weill Medical College of Cornell University | Endocarditis, Bacterial | 10/08 | 10/08 | | |
NCT01175707: Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting |
|
|
| Terminated | 4 | 80 | US | Daptomycin, Cubicin, Vancomycin | Cubist Pharmaceuticals LLC | Complicated Skin or Skin Structure Infection | 11/11 | 11/11 | | |
NCT01287832: Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs) |
|
|
| Terminated | 4 | 11 | US | Vancomycin, Daptomycin | St. John Health System, Michigan, Henry Ford Health System, Cubist Pharmaceuticals LLC | Bacteremia | 01/12 | 01/12 | | |
| Completed | 4 | 650 | Europe | Daptomycin, Cubicin, Cefuroxime | Hannover Medical School, Novartis | Wound Infection | 03/12 | 03/12 | | |
RENSE, NCT01104662: Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment |
|
|
| Terminated | 4 | 92 | US | Vancomycin, Daptomycin, Cubicin, Semi-Synthetic Penicillin, SSP, nafcillin, oxacillin, cloxacillin | Cubist Pharmaceuticals LLC | Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment | 06/12 | 06/12 | | |
| Completed | 4 | 250 | US | Daptomycin, Cubicin, Vancomycin | Cubist Pharmaceuticals LLC | Staphylococcal Skin Infections | 09/12 | 10/12 | | |
NCT01549613: Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections |
|
|
| Completed | 4 | 104 | US | Daptomycin, Vancomycin | University of Cincinnati | Cellulitis, Skin Infections | 07/13 | 07/13 | | |
NCT00711802 / 2015-002778-19: Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections |
|
|
| Completed | 4 | 396 | US, RoW | Daptomycin, Cubicin, Standard of Care (SOC), nafcillin, oxacillin, cloxacillin | Cubist Pharmaceuticals LLC | Skin Diseases, Infectious | 10/13 | 10/13 | | |
NCT01196169: Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty |
|
|
| Terminated | 4 | 28 | US | Daptomycin, Cubicin, Vancomycin | Mountain Home Research & Education Corporation, East Tennessee State University, Cubist Pharmaceuticals LLC | Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus | 03/14 | 03/14 | | |
NCT01626560: The Effects of Daptomycin and Cytokines Production in Comparison With Vancomycin |
|
|
| Completed | 4 | 20 | RoW | Daptomycin, Vancomycin | Hospital Universitario Evangelico de Curitiba | Cellulitis | 03/15 | 03/15 | | |
NCT01728376 / 2012-003447-29: Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005) |
|
|
| Completed | 4 | 82 | NA | Daptomycin, Cubicin, Comparator | Cubist Pharmaceuticals LLC | Bacteremia | 01/16 | 01/16 | | |
